Rocket Pharmaceuticals Inc expected to post a loss of 79 cents a share - Earnings Preview

Rocket Pharmaceuticals

04/08/2023 16:15

* Rocket Pharmaceuticals Inc  RCKT.OQ   RCKT.O  is expected
to show no change in quarterly revenue when it reports 
results on August 7 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Rocket
Pharmaceuticals
Inc is for a loss of 79 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 13 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Rocket
Pharmaceuticals Inc is $51.5​, above​ its last closing price
of $17.72. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -0.86       -0.85      -0.73     Beat    14.3
 Dec. 31 2023  -0.79       -0.80      -0.92     Missed  -14.6
 Sep. 30 2022  -0.80       -0.79      -0.87     Missed  -10.2​
 Jun. 30 2022  -0.66       -0.68      -0.83     Missed  -21.6
 ​​Mar.        -0.72       -0.71      -0.67     Beat    5.6
 31 2022                                                
 Dec. 31 2021  -0.76       -0.76      -0.69     Beat    9.6​
 Sep. 30 2021  -0.61       -0.61      -0.79     Missed  -30.3
 Jun. 30 2021  -0.67       -0.65      -0.55     Beat    15.3
 This summary was machine generated August 4 at 15:15 GMT.  All
figures in US dollars  unless otherwise stated